AACR 2019 Presentations Highlight CX-2009, a First-In-Class Probody Drug Conjugate Targeting Novel Tumor Antigen, CD166 - Associated Press https://t.co/YLVSq31ye5
— IDRO (@IDROOhio) April 2, 2019
from Twitter https://twitter.com/IDROOhio
April 02, 2019 at 04:02AM
No comments:
Post a Comment